Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
This article was originally published in RPM Report
Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.
You may also be interested in...
Medicare price negotiation is not a new idea – nor is the concept of using the Presidential megaphone to talk down drug prices. Will Trump and Twitter turn it into something bigger?
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.